Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1 Active not recruiting 3 enrolled Masonic Cancer Center, University of Minnesota National Cancer Institute (NCI) · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer.

Timeline

Start: 2024-07-11
Primary completion: 2026-03-26
Completion: 2027-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FT536	Cell therapy	3e+06 cells	Intrathecal
Subject	FT536	Cell therapy	1e+08 cells	Intrathecal
Subject	FT536	Cell therapy	3e+08 cells	Intrathecal
Subject	FT536	Cell therapy	1e+09 cells	Intrathecal
Background	CY	Unknown	300 mg/m2	Intravenous
Background	Fludarabine	Small molecule	25 mg/m2	Intravenous

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Summary

Timeline

Drugs

Indications